Industry Strength Score
32/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
CYBIN INC (HELP) Stock Price & Overview
NASDAQ:HELP • CA23256X4075
Current stock price
5.15 USD
-0.16 (-3.01%)
At close:
5.35 USD
+0.2 (+3.88%)
After Hours:
The current stock price of HELP is 5.15 USD. Today HELP is down by -3.01%. In the past month the price increased by 0.59%.
HELP Key Statistics
1-Month Range4.85 - 6.2586
Current HELP stock price positioned within its 1-month range.
- Market Cap
- 265.895M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- N/A
- Dividend Yield
- N/A
HELP Stock Performance
Today
-3.01%
1 Week
-8.20%
1 Month
+0.59%
3 Months
-22.21%
Longer-term
6 Months N/A
1 Year N/A
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
HELP Stock Chart
HELP Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to HELP.
Chartmill TA Rating
Chartmill Setup Rating
HELP Earnings
Next Earnings DateJun 29, 2026
Last Earnings DateFeb 13, 2026
PeriodQ3 / 2026
EPS Reported-CA$1.39
Revenue Reported
EPS Surprise -103.61%
Revenue Surprise %
HELP Forecast & Estimates
Analysts
Analysts85
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A
HELP Financial Highlights
Income Statements
Revenue(TTM)N/A
Net Income(TTM)N/A
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%N/A
EPS 1Y (TTM)N/A
Revenue 1Y (TTM)N/A
HELP Ownership
Ownership
Inst Owners51.91%
Shares51.63M
Float44.26M
Ins Owners4.03%
Short Float %7.54%
Short Ratio2.67
HELP Industry Overview
HELP operates in the Pharmaceuticals sub-industry within the Health Care sector. This group contains 29 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
48/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
32%
Outperformed 32% of sub-industries
3 Month Rank
63%
Outperformed 63% of sub-industries
6 Month Rank
26%
Outperformed 26% of sub-industries
Industry Fundamentals & Breadth
- Members
- 29
- New Highs
- 3.5%
- New Lows
- 10.3%
- Average ROE
- 17.5%
- Average Profit Margin
- 9.9%
- Average Operating Margin
- 19%
- Average P/E
- 5.2
- Average Fwd P/E
- 17.7
- Average Debt/Equity
- 0.5
HELP Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 22.63 | 883.029B | ||
| JNJ | JOHNSON & JOHNSON | 17.91 | 553.619B | ||
| MRK | MERCK & CO. INC. | 11.43 | 269.662B | ||
| PFE | PFIZER INC | 8.81 | 151.879B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.41 | 123.709B | ||
| ZTS | ZOETIS INC | 16.14 | 48.347B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.57 | 28.899B | ||
| VTRS | VIATRIS INC | 6.03 | 17.396B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.39 | 11.171B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 10.626B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.109B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.971B | ||
| CORT | CORCEPT THERAPEUTICS INC | 35.54 | 4.948B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About HELP
Company Profile
Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. The company is headquartered in Toronto, Ontario and currently employs 50 full-time employees. The company went IPO on 2018-01-05. The firm creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The firm is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. The company has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The firm operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.
Company Info
IPO: 2018-01-05
CYBIN INC
5600-100 King St West
TORONTO ONTARIO CA
Employees: 50
Phone: 19087648385
CYBIN INC / HELP FAQ
What does HELP do?
Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. The company is headquartered in Toronto, Ontario and currently employs 50 full-time employees. The company went IPO on 2018-01-05. The firm creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The firm is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. The company has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The firm operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.
What is the stock price of CYBIN INC today?
The current stock price of HELP is 5.15 USD. The price decreased by -3.01% in the last trading session.
Does HELP stock pay dividends?
HELP does not pay a dividend.
How is the ChartMill rating for CYBIN INC?
HELP has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Can you provide the number of employees for CYBIN INC?
CYBIN INC (HELP) currently has 50 employees.
When does CYBIN INC (HELP) report earnings?
CYBIN INC (HELP) will report earnings on 2026-06-29, after the market close.